Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy.
adherence
antiretroviral therapies (ART)
direct healthcare costs
drug utilization
healthcare resource consumption
human immunodeficiency virus (HIV)
persistence
real-word evidence
tenofovir alafenamide (TAF)-based regimens
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
21 02 2023
21 02 2023
Historique:
received:
31
01
2023
revised:
16
02
2023
accepted:
17
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
This real-world analysis conducted on administrative databases of a sample of Italian healthcare entities was aimed at describing the role of therapeutic pathways and drug utilization in terms of adherence, persistence, and therapy discontinuation in HIV-infected patients under antiretroviral therapies (ART) and Tenofovir Alafenamide (TAF)-based regimens on healthcare resource consumption and related direct healthcare costs. Between 2015 and 2019, adults (≥18 years) prescribed with TAF-based therapies were identified and characterized in the year prior to the first prescription (index-date) for TAF-based therapies and followed-up until the end of data availability. Overall, 2658 ART-treated patients were included, 1198 of which were under a TAF-based regimen. TAF-based therapies were associated with elevated percentages of adherence (83.3% patients with proportion of days covered, PDC > 95% and 90.6% with PDC > 85%) and persistence (78.5%). The discontinuation rate was low in TAF-treated patients, ranging from 3.3% in TAF-switchers to 5% in naïve. Persistent patients had lower overall mean annual healthcare expenditures (EUR 11,106 in persistent vs. EUR 12,380 in non-persistent,
Identifiants
pubmed: 36900813
pii: ijerph20053789
doi: 10.3390/ijerph20053789
pmc: PMC10000772
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Adenine
JAC85A2161
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Curr HIV/AIDS Rep. 2018 Feb;15(1):49-59
pubmed: 29380227
PLoS One. 2020 Dec 17;15(12):e0243529
pubmed: 33332394
AIDS Care. 2019 May;31(5):599-608
pubmed: 30309269
Sci Rep. 2018 Feb 16;8(1):3133
pubmed: 29453393
Pharmacotherapy. 2016 Apr;36(4):385-401
pubmed: 26923931
HIV Clin Trials. 2002 Sep-Oct;3(5):355-60
pubmed: 12407484
J Manag Care Spec Pharm. 2019 Jan;25(1):88-93
pubmed: 30589631
AIDS Res Ther. 2020 Apr 1;17(1):12
pubmed: 32238169
AIDS. 2012 Jan 28;26(3):335-43
pubmed: 22089374
Clinicoecon Outcomes Res. 2014 Dec 22;7:27-35
pubmed: 25565872
Medicine (Baltimore). 2016 Apr;95(15):e3361
pubmed: 27082595
Transl Behav Med. 2022 Jan 18;12(1):
pubmed: 34379122
AIDS Behav. 2011 Oct;15(7):1381-96
pubmed: 21468660
Value Health. 2020 Oct;23(10):1324-1331
pubmed: 33032776
Health Econ Rev. 2014 Dec;4(1):15
pubmed: 26208918
Int J Infect Dis. 2020 Feb;91:44-49
pubmed: 31740407
HIV Med. 2015 Jan;16(1):38-47
pubmed: 25105798
J Infect. 2017 Apr;74(4):401-407
pubmed: 28143756
J Patient Rep Outcomes. 2022 Mar 26;6(1):27
pubmed: 35347476
HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
pubmed: 17956829
J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):245-251
pubmed: 31343455
AIDS Behav. 2015 Apr;19(4):601-11
pubmed: 25342151
BMC Infect Dis. 2019 Sep 5;19(1):775
pubmed: 31488063
Expert Opin Drug Saf. 2021 Apr;20(4):397-409
pubmed: 33557651
Medicine (Baltimore). 2016 Oct;95(43):e4973
pubmed: 27787358
AIDS Res Ther. 2021 Jun 26;18(1):36
pubmed: 34174904
BMC Health Serv Res. 2018 Sep 6;18(1):691
pubmed: 30189882
Int J Nurs Sci. 2018 Apr 14;5(2):162-167
pubmed: 31406819
Int J Environ Res Public Health. 2020 Dec 03;17(23):
pubmed: 33287274